Bertilimumab

Drug Profile

Bertilimumab

Alternative Names: Anti-eotaxin human monoclonal antibody - MedImmune; CAT-213; iCo-008

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Cambridge Antibody Technology; iCo Therapeutics; Immune Pharmaceuticals Inc
  • Class Antiallergics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Chemokine CCL11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bullous pemphigoid; Crohn's disease; Ulcerative colitis
  • Phase I Atopic dermatitis; Non-alcoholic steatohepatitis
  • Preclinical Wet age-related macular degeneration
  • No development reported Allergic conjunctivitis; Asthma
  • Discontinued Allergic rhinitis; Ovarian cancer

Most Recent Events

  • 20 Feb 2018 Immune Pharmaceuticals plans a phase II/III trial for Bullous Pemphigoid in 2019 (CTP#293326)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-conjunctivitis in Canada (Ophthalmic)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Asthma in Israel (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top